Human single-chain variable fragment antibody expressed in E. coli with optimal in vitro cross-neutralizing and no enhancing activity

Qi, 2008, Biological characteristics of dengue virus and potential targets for drug design, Acta Biochim Biophys Sin, 40, 91, 10.1111/j.1745-7270.2008.00382.x Rice, 1985, Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution, Science, 229, 726, 10.1126/science.4023707 Guzman, 2010, Dengue: a continuing global threat, Nat Rev Microbiol, 8, S7, 10.1038/nrmicro2460 Kliks, 1989, Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever, Am J Trop Med Hyg, 40, 444, 10.4269/ajtmh.1989.40.444 Whitehead, 2007, Prospects for a dengue virus vaccine, Nat Rev Microbiol, 5, 518, 10.1038/nrmicro1690 Murrell, 2011, Review of dengue virus and the development of a vaccine, Biotechnol Adv, 29, 239, 10.1016/j.biotechadv.2010.11.008 2016, 349 Schieffelin, 2010, Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient, Virol J, 7, 28, 10.1186/1743-422X-7-28 Dejnirattisai, 2010, Cross-reacting antibodies enhance dengue virus infection in humans, Science, 328, 745, 10.1126/science.1185181 Bernardo, 2009, Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes, Clin Vaccine Immunol, 16, 1829, 10.1128/CVI.00191-09 de Alwis, 2011, In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection, PLoS Negl Trop Dis, 5, e1188, 10.1371/journal.pntd.0001188 de Alwis, 2012, Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions, Proc Natl Acad Sci U S A, 109, 7439, 10.1073/pnas.1200566109 Teoh, 2012, The structural basis for serotype-specific neutralization of dengue virus by a human antibody, Sci Transl Med, 4, 10.1126/scitranslmed.3003888 Zou, 2012, Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1, Antivir Res, 95, 216, 10.1016/j.antiviral.2012.06.010 Costin, 2013, Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop, J Virol, 87, 52, 10.1128/JVI.02273-12 Setthapramote, 2012, Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection, Biochem Biophys Res Commun, 423, 867, 10.1016/j.bbrc.2012.06.057 Sasaki, 2013, Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection, Antivir Res, 98, 423, 10.1016/j.antiviral.2013.03.018 Presta, 2003, Antibody engineering for therapeutics, Curr Opin Struct Biol, 13, 519, 10.1016/S0959-440X(03)00103-9 Farajnia, 2014, Development trends for generation of single-chain antibody fragments, Immunopharmacol Immunotoxicol, 36, 297, 10.3109/08923973.2014.945126 Kurosu, 2010, Highly efficient rescue of dengue virus using a co-culture system with mosquito/mammalian cells, Biochem Biophys Res Commun, 394, 398, 10.1016/j.bbrc.2010.02.181 Pitaksajjakul, 2014, Antibody germline characterization of cross-neutralizing human IgGs against 4 serotypes of dengue virus, Biochem Biophys Res Commun, 446, 475, 10.1016/j.bbrc.2014.02.131 Palmer, 2004, Preparation and extraction of insoluble (inclusion-body) proteins from Escherichai coli, Curr Protoc Protein Sci, Chapter 6, 10.1002/0471140864.ps0603s38 Bu, 2013, Expression and purification of a novel therapeutic single-chain variable fragment antibody against BNP from inclusion bodies of Escherichia coli, Protein Expr Purif, 92, 203, 10.1016/j.pep.2013.10.002 Konishi, 2010, A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus layers of semi-adherent K562 cells, J Virol Methods, 163, 360, 10.1016/j.jviromet.2009.10.026 Chan, 2013, Therapeutic antibodies as a treatment option for dengue, Expert Rev Anti Infect Ther, 11, 1, 10.1586/14787210.2013.839941 Poungpair, 2014, Generation of human single-chain variable fragment antibodies specific to dengue virus non-structural protein 1 that interfere with the virus infectious cycle, mAbs, 6, 474, 10.4161/mabs.27874 Saokaew, 2014, Human monoclonal single-chain antibodies specific to dengue virus envelope protein, Lett Appl Microbiol, 58, 270, 10.1111/lam.12186 Boss, 1984, Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in E. coli, Nucleic Acids Res, 12, 3791, 10.1093/nar/12.9.3791 Nelson, 2010, Antibody fragments: hope and hype, mAbs, 2, 77, 10.4161/mabs.2.1.10786 Ahmad, 2012, scFv antibody: principles and clinical application, Clin Dev Immunol, 2012, 980250, 10.1155/2012/980250 Francis, 2010, Strategies to optimize protein expression in E. coli, Curr Protoc Protein Sci, 5, 10.1002/0471140864.ps0524s61 Bhatia, 2010, Single-chain fragment variable antibody against the capsid protein of bovine immunodeficiency virus and its use in ELISA, J Virol Methods, 167, 68, 10.1016/j.jviromet.2010.03.012 Lobstein, 2012, SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded protein in its cytoplasm, Microb Cell Fact, 11, 1, 10.1186/1475-2859-11-56 Cheng, 2014, Functional production of a soluble and secreted single-chain antibody by a bacterial secretion system, PLoS One, 9, e97367, 10.1371/journal.pone.0097367 Kipriyanov, 1996, Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion, Protein Eng, 9, 203, 10.1093/protein/9.2.203 Smallshaw, 1999, Synthesis, cloning and expression of the single-chain Fv gene of the HPr-specific monoclonal antibody, Jel42: determination of binding constants with wild-type and mutant HPrs, Protein Eng, 12, 623, 10.1093/protein/12.7.623 Robinson, 2014, Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria, Nat Commun, 6, 1 Clark, 1998, Refolding of recombinant proteins, Curr Opin Biotechnol, 9, 157, 10.1016/S0958-1669(98)80109-2 Kudou, 2011, Refolding single-chain antibody (scFv) using lauroyl-L-glutamate as a solubilization detergent and arginine as a refolding additive, Protein Expr Purif, 77, 68, 10.1016/j.pep.2010.12.007 Yamaguchi, 2014, Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies, Biomolecules, 4, 235, 10.3390/biom4010235 Eiberle, 2010, Technical refolding of proteins: do we have freedom to operate?, Biotechnol J, 5, 547, 10.1002/biot.201000001 Byers, 2015, Influence of FcγRIIa-expressing cells on the assessment of neutralizing and enhancing serum antibodies elicited by a live-attenuated tetravalent dengue vaccine, OFID, 2, ofv172, 10.1093/ofid/ofv172 Tanu, 2013, Dengue virus neutralization in cells expressing Fc gamma receptors, PLoS One, 8, 1 Klein, 2009, Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10, Proc Natl Acad Sci Unit States Am, 106, 7385, 10.1073/pnas.0811427106 Wahala, 2011, The human antibody response to dengue virus infection, Viruses, 3, 2374, 10.3390/v3122374 Tsai, 2013, High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary infection, J Virol, 87, 12562, 10.1128/JVI.00871-13 Lin, 2012, Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay, PLoS Negl Trop Dis, 6, 1, 10.1371/journal.pntd.0001447 Huang, 2010, The dengue virus type 2 envelope protein fusion is essential for membrane fusion, Virology, 396, 305, 10.1016/j.virol.2009.10.027 Williams, 2013, Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies, PLoS Pathog, 9, 10.1371/journal.ppat.1003157